Trials / Completed
CompletedNCT00906191
Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects
An Open-Label, Single-Dose, Nonrandomized Study Of The Mass Balance And Metabolic Disposition Of Orally Administered 14C-Labeled SAM-531 In Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to investigate how quickly and to what extent the 14-Carbon labeled SAM-531 is absorbed into the bloodstream, converted and eliminated from the body after oral administration in healthy male subjects. As 14-Carbon labeled SAM-531 is radioactive, this enables the compound to be traced in blood, urine and feces.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAM-531 |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-05-21
- Last updated
- 2009-08-26
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00906191. Inclusion in this directory is not an endorsement.